Literature DB >> 10816344

Amino acid uptake and regulation in multicellular hepatoma spheroids.

T M Pawlik1, W W Souba, T J Sweeney, B P Bode.   

Abstract

BACKGROUND: Cancer cells maintained in monolayer tissue culture are frequently used to study tumor biology and nutrient uptake, but there is a concern that this system may not fully reflect clinical tumor physiology. Because cells grown in a 3-D configuration more closely resemble an in vivo environment, a model was developed and characterized for the growth of SK-Hep human hepatoma cells in suspension as multicellular tumor spheroids (MTS). The measurement of nutrient uptake in such a system has never been established.
MATERIALS AND METHODS: SK-Hep cultures were initiated as single cell suspensions and grown as MTS in siliconized spinner flasks. The transport of several individual amino acids (arginine, glutamate, leucine, alpha-(N-methylamino)isobutyric acid (MeAIB), and glutamine (GLN)) was measured in SK-Hep single cell suspensions and MTS (0. 50-0.60 mm diameter) by a radiotracer/rapid filtration technique, as was the regulation of glutamine uptake by phorbol esters. l-[(3)H]GLN uptake was also measured in larger spheroids (0.85-1.5 mm diameter). MTS cellularity was evaluated by histological examination, and single cell integrity after the transport assay was confirmed by scanning electron microscopy (SEM).
RESULTS: SK-Hep MTS displayed gradients of cellular morphology and staining, with central necrosis visible at diameters >0.8 mm. Single cell suspensions endured the rapid filtration technique based on functional Na(+)-dependent uptake rates and SEM analysis. Of all amino acids tested, only GLN transport rates were visibly affected by growth format. In small MTS, Na(+)-dependent GLN uptake was diminished by 40%, but was 40-53% higher in MTS >1 mm displaying central necrosis, when compared to single cell suspensions. Likewise, slight parallel changes in glutamine transporter ATB(0) mRNA levels were observed in Northern blot analysis. Finally, phorbol ester-dependent GLN transport down-regulation (by 40-50%), previously established in SK-Hep monolayers, remained operative in all cell formats tested.
CONCLUSIONS: The data suggest that the tumor microenvironment differentially impacts the uptake of specific nutrients despite the conservation of key regulatory pathways. This MTS technique may prove useful for further studies on the role of nutrient transport in nascent tumor growth. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10816344     DOI: 10.1006/jsre.2000.5888

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  5 in total

1.  Preclinical models for interrogating drug action in human cancers using Stable Isotope Resolved Metabolomics (SIRM).

Authors:  Andrew N Lane; Richard M Higashi; Teresa W-M Fan
Journal:  Metabolomics       Date:  2016-06-29       Impact factor: 4.290

2.  Glutamine availability up-regulates expression of the amino acid transporter protein ASCT2 in HepG2 cells and stimulates the ASCT2 promoter.

Authors:  Claire I Bungard; John D McGivan
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

Review 3.  Three-Dimensional Spheroids as In Vitro Preclinical Models for Cancer Research.

Authors:  Bárbara Pinto; Ana C Henriques; Patrícia M A Silva; Hassan Bousbaa
Journal:  Pharmaceutics       Date:  2020-12-06       Impact factor: 6.321

Review 4.  Resolving Metabolic Heterogeneity in Experimental Models of the Tumor Microenvironment from a Stable Isotope Resolved Metabolomics Perspective.

Authors:  Teresa W-M Fan; Richard M Higashi; Yelena Chernayavskaya; Andrew N Lane
Journal:  Metabolites       Date:  2020-06-15

5.  Stable Isotope-Resolved Metabolomics Shows Metabolic Resistance to Anti-Cancer Selenite in 3D Spheroids versus 2D Cell Cultures.

Authors:  Teresa W-M Fan; Salim S El-Amouri; Jessica K A Macedo; Qing Jun Wang; Huan Song; Teresa Cassel; Andrew N Lane
Journal:  Metabolites       Date:  2018-07-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.